Author:
Imafuku Shinichi,Ohata Chika,Okubo Yukari,Tobita Rie,Saeki Hidehisa,Mabuchi Tomotaka,Hashimoto Yuki,Murotani Kenta,Kitabayashi Hiroki,Kanai Yasumasa
Subject
Dermatology,Molecular Biology,Biochemistry
Reference36 articles.
1. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials;Blauvelt;J. Eur. Acad. Dermatol. Venereol.,2019
2. World Health Organization, Global report on psoriasis, 2016. 〈https://apps.who.int/iris/handle/10665/204417〉 (Accessed 16 December 2021).
3. Treatment approaches to moderate to severe psoriasis;Gisondi;Int. J. Mol. Sci.,2017
4. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis;Papp;Br. J. Dermatol.,2016
5. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study;Lebwohl;Am. J. Clin. Dermatol.,2019
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献